Completed PHASE2 INTERVENTIONAL 5-arm NCT02585869

Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI-1027 in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

Sponsor: NeuroBo Pharmaceuticals Inc.

Conditions Hypercholesterolemia Hypertriglyceridemia

Interventions Gemcabene 150 mg Gemcabene 300 mg Gemcabene 600 mg Gemcabene 900 mg Placebo

Updated 8 times since 2017 Last updated: Apr 8, 2020 Started: Dec 31, 1999 Primary completion: Jun 30, 2001 Completion: Jun 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hypercholesterolemia and Hypertriglyceridemia, this trial is completed. The trial is conducted by NeuroBo Pharmaceuticals Inc. and has accumulated 8 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2020 — Jan 2021 [monthly]

Completed PHASE2
May 2020 — Sep 2020 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Apr 2020 — May 2020 [monthly]

Completed PHASE2
Feb 2017 — Apr 2020 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NeuroBo Pharmaceuticals Inc.

Data source: NeuroBo Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.